TGFβ pathway abrogation in CRC can occur through mutation of either TGFβ‐receptor 1 (TGFBR1) or TGFBR2. Furthermore, TGFβ pathway inactivation can occur via loss of heterozygosity (LOH) of chromosome 18q, where SMAD2 and SMAD4, two downstream mediators of TGFβ signalling, are located. Here, TGFB1 is linked to colorectal carcinoma.